Form 8-K - Current report:
SEC Accession No. 0000950170-23-010286
Filing Date
2023-03-28
Accepted
2023-03-28 16:11:18
Documents
13
Period of Report
2023-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bmea-20230328.htm   iXBRL 8-K 52483
2 EX-99.1 bmea-ex99_1.htm EX-99 232750
  Complete submission text file 0000950170-23-010286.txt   417777

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bmea-20230328.xsd EX-101.SCH 2481
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bmea-20230328_pre.xml EX-101.PRE 9848
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bmea-20230328_lab.xml EX-101.LAB 13350
7 EXTRACTED XBRL INSTANCE DOCUMENT bmea-20230328_htm.xml XML 4704
Mailing Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063
Business Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40335 | Film No.: 23769656
SIC: 2834 Pharmaceutical Preparations